Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Bladder Cancer Specialty Channel

Bladder Cancer
Specialty Channel
News
03/08/2024

Allison Casey

Allison Casey
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA...
03/08/2024
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
News
03/07/2024
Allison Casey
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study,...
03/07/2024
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
News
02/29/2024
Allison Casey
Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.
Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.
Final, updated results from the...
02/29/2024
Oncology
News
02/29/2024
Allison Casey
According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...
According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...
According to 5-year follow-up...
02/29/2024
Oncology
News
02/15/2024

Allison Casey

Allison Casey
According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...
According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...
According to a primary analysis...
02/15/2024
Oncology
Andrea Apolo, MD, National Cancer Institute
Conference Coverage
02/05/2024

Featuring Andrea Apolo, MD 

Featuring Andrea Apolo, MD 
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers...
02/05/2024
Oncology
David Aggen, MD, PhD
Conference Coverage
01/30/2024

Featuring David Aggen, MD, PhD

Featuring David Aggen, MD, PhD ...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights...
01/30/2024
Oncology
Michiel van der Heijden, MD 
Conference Coverage
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Conference Coverage
01/26/2024

Stephanie Holland

Stephanie Holland
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the...
01/26/2024
Oncology
Conference Coverage
01/26/2024
Allison Casey
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a...
01/26/2024
Oncology

News

News
03/08/2024

Allison Casey

Allison Casey
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.
On March 7, 2024, the FDA...
03/08/2024
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
News
03/07/2024
Allison Casey
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study, enfortumab vedotin plus pembrolizumab significantly improved progression-free survival and overall survival compared to chemotherapy among patients with untreated advanced urothelial carcinoma.
According to a phase 3 study,...
03/07/2024
Oncology
News
02/29/2024
Allison Casey
Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.
Final, updated results from the phase 3 POUT trial added further support to the use of adjuvant chemotherapy for patients with upper tract urothelial cancer who have undergone nephroureterectomy.
Final, updated results from the...
02/29/2024
Oncology
News
02/29/2024
Allison Casey
According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...
According to 5-year follow-up data from a phase 2 trial, the use of 2 induction courses of bacillus Calmette-Guèrin without maintenance therapy may provide an alternate treatment option for patients with high-risk non-muscle-invasive bladder...
According to 5-year follow-up...
02/29/2024
Oncology
News
02/15/2024

Allison Casey

Allison Casey
According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...
According to a primary analysis of a cohort from the phase 3 TROPHY-U-01 trial, sacituzumab govitecan plus pembrolizumab showed promising antitumor activity with a manageable toxicity profile among patients with metastatic urothelial cancer...
According to a primary analysis...
02/15/2024
Oncology
Andrea Apolo, MD, National Cancer Institute
Conference Coverage
02/05/2024

Featuring Andrea Apolo, MD 

Featuring Andrea Apolo, MD 
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers...
02/05/2024
Oncology
David Aggen, MD, PhD
Conference Coverage
01/30/2024

Featuring David Aggen, MD, PhD

Featuring David Aggen, MD, PhD ...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights...
01/30/2024
Oncology
Michiel van der Heijden, MD 
Conference Coverage
01/26/2024

Featuring Michiel van der Heijden, MD 

Featuring Michiel van der Heijden, MD...
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Conference Coverage
01/26/2024

Stephanie Holland

Stephanie Holland
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the...
01/26/2024
Oncology
Conference Coverage
01/26/2024
Allison Casey
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a...
01/26/2024
Oncology

Interactive Features

Quiz
10/19/2023
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to...
10/19/2023
Oncology
Quiz
02/10/2023
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the...
02/10/2023
Oncology
Quiz
12/01/2022
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter...
12/01/2022
Oncology
Quiz
10/18/2022
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral...
10/18/2022
Oncology
Quiz
09/02/2022
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in...
09/02/2022
Oncology
Test Your Knowledge
02/20/2022
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab...
02/20/2022
Oncology
Quiz
07/01/2021
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was...
07/01/2021
Oncology
Quiz
07/01/2021
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated...
07/01/2021
Oncology
Test Your Knowledge
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement